What’s New in CLL?
- Help move CLL patients to the front of the COVID-19 vaccine line by using our letter asking your state’s health department to move cancer patients to the front of the vaccine line. “Click, fill, send!“
- ASH 2020: Dr. Meghan Thompson Interview – Venetoclax Retreatment of Chronic Lymphocytic Leukemia (CLL) Patients after a Previous Venetoclax-Based Regimen
- ASH 2020: Dr. Jennifer Brown on combination duvelisib + venetoclax for patients with relapsed/refractory chronic lymphocytic leukemia (CLL)
- ASH 2020: Dr. Meghan Thompson – Can APR-246 Restore the Wild-Type Function of the P53 Gene in Chronic Lymphocytic Leukemia (CLL)
Get The Best Care for Your Chronic Lymphocytic Leukemia (CLL)
The CLL Society Inc. is a patient–centric, physician–curated nonprofit organization focused on
patient education, support and research. Dedicated to addressing the unmet needs of the (CLL) chronic lymphocytic leukemia and
related blood cancer communities, we explain the rapidly changing therapeutic landscape and the importance of clinical trials,
support and build patient networks, engage in research and educate providers and patients.
CLL Society Expert Access™
Access to a CLL expert is critical to ensure receiving the best possible care and has proven to improve survival. In partnership with Verastem Oncology (Expert Access Founding Supporter), Genentech, and InfiniteMD, the CLL Society is proud to offer this free second opinion program for CLL patients.
We Are in this Together
-
Pingback: ABT-199 (venetoclax) in Combination Treatment for CLL